Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for parkinson's disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on parkinson's disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on parkinson's disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
: Affiliations 1 Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Clintrex, Sarasota, FL, USA. Electronic address: firstname.lastname@example.org. 2 Department of Neurology, Emory University, Atlanta, GA, USA. 3 Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH, USA. 4 Department of Neurology, University of South Florida, Tampa, FL, USA. 5 Barrow Neurological Institute, Phoenix, AZ, USA. 6 Parkinson'sDisease and Movement Disorders (...) and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA. 7 University of Kansas Medical Center, University of Kansas, Kansas City, KS, USA. 8 Clintrex, Sarasota, FL, USA. 9 Sunovion, Marlborough, MA, USA. PMID: 31818699 DOI: Item in Clipboard Full-text links Cite Abstract Background: Many patients with Parkinson'sdisease have potentially disabling off episodes that are not predictably responsive to levodopa. In this study, we assessed the safety and efficacy of apomorphine sublingual film
Assessment of an Objective Method of Dyskinesia Measurement in Parkinson'sDisease. The goal of this study was to validate an objective method of measuring levodopa induced dyskinesia in Parkinson'sdisease (PD).To characterize agreement between the clinician-based measure and a force plate, we assessed dyskinesia in PD subjects participating in a randomized and blinded clinical trial of an adenosine A2A anatagonist. Convergent validity and intra-class correlations were evaluated between
Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with ParkinsonDisease. Neurogenic orthostatic hypotension (nOH) is associated with neurodegenerative conditions, may cause symptoms of end-organ hypoperfusion, increases fall risk, and can negatively impact quality of life. Droxidopa is approved for the treatment of symptomatic nOH in adults. As the largest subpopulation of patients with nOH has a diagnosis of Parkinsondisease (PD
and Uncertainties Conclusions and Reasons Analysis of Condition ? The condition treated was advanced Parkinson'sdisease which is operationally defined as patients taking levodopa and experiencing OFF episodes. Istradefylline was given to these patients as adjunctive treatment. The pivotal trials were adequate for investigating effects on istradefylline on adult patients with advanced Parkinson'sdisease. Current Treatment Options ? There are many approved treatments as adjunctive therapy for patients (...) Istradefylline (Nourianz) - Parkinson'sdisease CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022075Orig1s000 CLINICAL REVIEW(S) (b) (4) Clinical Review Natalie Branagan, MD NDA 022075 Nourianz/istradefylline CLINICAL REVIEW Application Type NDA Application Number(s) 022075 Priority or Standard Class 2 Resubmission Submit Date(s) February 27, 2019 Received Date(s) February 27, 2019 PDUFA Goal Date August 27, 2019 Division/Office DNP Reviewer Name(s) Natalie Branagan, MD Review
of group assignments. Both interventions were home based, requiring 30-45 min training three times per week for 6 months. Both groups received a motivational app and remote supervision. Home trainers were enhanced with virtual reality software and real-life videos providing a so-called exergaming experience (ie, exercise enhanced by gamified elements). The primary outcome was the between-group difference in the Movement Disorders Society-Unified Parkinson'sDisease Rating Scale (MDS-UPDRS) motor (...) Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson'sdisease: a double-blind, randomised controlled trial High-intensity aerobic exercise might attenuate the symptoms of Parkinson'sdisease, but high-quality evidence is scarce. Moreover, long-term adherence remains challenging. We aimed to evaluate the effectiveness of aerobic exercise-gamified and delivered at home, to promote adherence-on relieving motor symptoms in patients with Parkinson'sdisease with mild
with Parkinson’sdisease, the cells in the brain that produce dopamine, a neurotransmitter important for controlling movement, begin to die and the amount of dopamine in the brain decreases. Inbrija contains levodopa which converts into dopamine in the brain and helps to restore dopamine levels, thereby improving the symptoms of the condition. Because Inbrija is inhaled, it can supply extra levodopa (and hence dopamine) quickly when needed during an ‘off’ period. What benefits of Inbrija have been shown (...) malignant syndrome or rhabdomyolysis. For the full list of side effects and restrictions, see the package leaflet. Why is Inbrija authorised in the EU? Studies show that Inbrija is effective at reducing symptoms during ‘off’ periods in patients with Parkinson’sdisease on levodopa/dopa-decarboxylase-inhibitor treatment. The safety of the medicine is in line with other similar medicines. Because it is inhaled, Inbrija provides rapid relief of symptoms, which improves patients’ quality of life
and written form. n Discussions should aim to achieve a balance between providing realistic information and promoting optimism. n Families and caregivers should be informed about the condition and available support services. DIAGNOSIS AND PROGRESSION n Parkinsondisease should be suspected in anyone with tremor, stiness, slowness, balance problems or gait disorders. n CT or MRI brain scanning should not be routinely used to diagnose Parkinsondisease. n Patients, especially young, who request genetic (...) to achieve a balance between providing realistic information and promoting optimism. n Families and caregivers should be informed about the condition and available support services. DIAGNOSIS AND PROGRESSION n Parkinsondisease should be suspected in anyone with tremor, stiness, slowness, balance problems or gait disorders. n CT or MRI brain scanning should not be routinely used to diagnose Parkinsondisease. n Patients, especially young, who request genetic testing should be assessed by a movement
Safinamide (Xadago) for the treatment of adult patients with idiopathic Parkinson'sdisease Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson'sdisease | Report | National Health Care Institute You are here: Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson'sdisease Search within English part of National Health Care Institute Search Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson'sdisease
Safinamide (Onstryv) - idiopathic Parkinson'sdisease Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1
effect of land-based therapies plus aquatic therapy in patients with PD who have FOG.The objective was to investigate the effectiveness of a multidisciplinary, intensive, motor-cognitive rehabilitation treatment (MIRT) in improving FOG and whether implementation with aquatic therapy (MIRT-AT) adds further benefits.The design consisted of a single-blind, parallel-group, 1:1 allocation ratio, randomized trial.The Department of ParkinsonDisease, Movement Disorders and Brain Injury Rehabilitation (...) Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Freezing of Gait in ParkinsonDisease: A Randomized Controlled Trial Freezing of gait (FOG) is one of the most disabling symptoms of Parkinsondisease (PD). Different land-based rehabilitation approaches based on motor and cognitive strategies can be effective in treating FOG. Although there are data about the efficacy of aquatic therapy in ameliorating this phenomenon, no study has explored the combined
Randomized trial of care management to improve Parkinsondisease care quality To test effects on care quality of Chronic Care Model-based Parkinsondisease (PD) management.This 2-group stratified randomized trial involved 328 veterans with PD in southwestern United States. Guided care management, led by PD nurses, was compared to usual care. Primary outcomes were adherence to 18 PD care quality indicators. Secondary outcomes were patient-centered outcome measures. Data sources were telephone (...) of the changes over time was in the positive Patient Health Questionnaire-2 depression screen for intervention minus usual care (-11.52 [95% CI -20.42, -2.62]).A nurse-led chronic care management intervention, Care Coordination for Health Promotion and Activities in Parkinson'sDisease (CHAPS), substantially increased adherence to PD quality of care indicators among veterans with PD, as documented in the EMR. Of 8 secondary outcomes assessed, a screening measure for depressive symptomatology was the only
Aquatic exercise improves motor impairments in people with Parkinson`s disease, with similar or greater benefits than land-based exercise: a systematic review What are the effects of aquatic exercise on disease severity, (non-)motor impairments, activity performance, fear of falling, and quality of life in people with Parkinson'sdisease (PD)? Does aquatic exercise have greater effects on these outcomes than other forms of exercise in people with PD?Systematic review and meta-analysis (...) in the Unified Parkinson'sDisease Rating Scale Part III (MD -4.6, 95% CI -7.5 to -1.7) in favour of aquatic exercise. Six studies compared aquatic exercise with land-based exercise after intervention (mean 7.2 weeks of training (SD 2.2); 159 participants). The effect of aquatic exercise was superior to land-based exercise on the Berg Balance Scale (MD 2.7, 95% CI 1.6 to 3.9), the Falls Efficacy Scale (MD -4.0, 95% CI -6.1 to -1.8) and the 39-item Parkinson'sDisease Questionnaire (MD -6.0, 95% CI -11.3
Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With ParkinsonDisease: Randomized Controlled Pilot Study Declining physical activity commonly occurs in people with Parkinsondisease (PD) and contributes to reduced functional capacity and quality of life.The purpose of this study was to explore the preliminary effectiveness, safety, and acceptability of a mobile health (mHealth)-mediated exercise program designed to promote sustained physical (...) . Daily steps and moderate-intensity minutes were measured using a step activity monitor for 1 week at baseline and again at 12 months. Secondary outcomes included the 6-Minute Walk Test, ParkinsonDisease Questionnaire 39 mobility domain, safety, acceptability, and adherence.Both groups increased daily steps, moderate-intensity minutes, and 6-Minute Walk Test, with no statistically significant between-group differences observed. In the less active subgroup, changes in daily steps and moderate
Bright light therapy for depression in Parkinsondisease: A randomized controlled trial To assess the efficacy of bright light therapy (BLT) in reducing depressive symptoms in patients with Parkinsondisease (PD) and major depressive disorder (MDD) compared to a control light.In this double-blind controlled trial, we randomized patients with PD and MDD to treatment with BLT (±10,000 lux) or a control light (±200 lux). Participants were treated for 3 months, followed by a 6-month naturalistic
Trunk Exercises Improve Gait Symmetry in ParkinsonDisease: A Blind Phase II Randomized Controlled Trial. Deficits in step-to-step symmetry and trunk muscle activations have been linked to falls in Parkinsondisease. Given such symptoms are poorly managed with anti-parkinsonian medications, alternate therapies are needed. This blind phase II randomized controlled trial sought to establish whether exercise can improve step-to-step symmetry in Parkinson disease.Twenty-four Parkinsondisease (...) , active interventions seem more suited to increasing independence and quality of life for people with Parkinson disease.Complete the self-assessment activity and evaluation online at http://www.physiatry.org/JournalCME CME OBJECTIVES: Upon completion of this article, the reader should be able to do the following: (1) Describe the effect deficits in trunk muscle function have on gait in individuals with Parkinsondisease; (2) Identify the benefits of targeted trunk exercises on step-to-step symmetry
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson`s disease: a randomised, double-blind, placebo-controlled phase 3 trial Patients with Parkinson'sdisease chronically treated with levodopa commonly have delayed or unpredictable onset of its benefits after oral intake. In this study, we assessed the safety and efficacy of CVT-301, a self-administered levodopa oral inhalation powder, for the treatment of patients (...) with Parkinson'sdisease during off periods.In this randomised, double-blind, placebo-controlled, phase 3 trial, patients were recruited at 65 sites in Canada, Poland, Spain, and the USA. Eligible participants were patients with Parkinson'sdisease aged 30-85 years, who had daily off periods of 2 h or longer and showed an improvement of 25% or greater in the Unified Parkinson'sDisease Rating Scale (UPDRS) motor score from off to on state after use of an oral levodopa plus a dopa-decarboxylase inhibitor
and intensity of treatment sessions was less than found in some recent trials, but are reflective of current NHS practice. The researchers suggest that future research could investigate more intensive physiotherapy and occupational therapy programmes, and focus on people with more severe Parkinson’sdisease. Share your views on the research. Why was this study needed? Parkinson’sdisease is a progressive neurological disorder associated with significant problems with movement, including trembling, stiffness (...) . Bibliography Deane K, Ellis-Hill C, Dekker K, et al. . Br J Occup Ther. 2003;66:193-200. Deane K, Ellis-Hill C, Dekker K, et al. .Br J Occup Ther. 2003;66:247-254. National Collaborating Centre for Chronic Conditions. London: Royal College of Physicians; 2006. NHS Choices. . London: Department Of Health; 2015. NICE. CG35. London: National Institute for Health and Care Excellence; 2006. Plant RP, Jones D, Ashburn A, et al. Evaluation of Physiotherapy in Parkinson’sDisease: Project Update: The Science
Relationship Between Respiratory Sensory Perception, Speech, and Swallow in Parkinson'sDisease. It has been suggested that sensory impairments contribute significantly to the motor deficits secondary to impaired sensorimotor integration in Parkinson'sdisease. Speech and swallowing are likely to become disordered in PD, and there is evidence that impaired upper airway sensation also contributes to these disorders.The goal of this study was to investigate the relationship between perception
Effects of Qigong Exercise on Non-Motor Symptoms and Inflammatory Status in Parkinson'sDisease: A Protocol for a Randomized Controlled Trial. Background: Non-motor symptoms such as sleep disturbance, cognitive decline, fatigue, anxiety, and depression in Parkinson'sdisease (PD) impact quality of life. Increased levels of pro-inflammatory cytokines in individuals with PD have been reported, which may contribute to non-motor symptoms. A mind-body exercise, Qigong, has demonstrated benefits (...) across different medical conditions. However, a lack of evidence causes clinicians and patients to be uncertain about the effects of Qigong in individuals with PD. This study will examine the effects of Qigong on non-motor symptoms and inflammatory status in individuals with PD. Methods: Sixty individuals with PD will be recruited. Qigong and sham Qigong group (n = 30 for each) will receive a 12-week intervention. Participants will practice their assigned exercise at home (2×/day) and attend